Background: Access to Antiretroviral Therapy (ART) 
Recommendation:Focus on patients younger than 40 years should be prioritized and comprehensive and
focused services friendly to the young need to be strengthened at the health facility level. 
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1.3Justification
This study aimed at identifying factors associated with virologic failure amongst patients on ART and with immunologic and/or clinical failure. These findings were of importance to future management of PLHIV with immunologic and/or clinical failure. In addition, the findings would be used to guide interventions that would avert possible virologic failure hence prolong the time that the patient stays on the same regimen without switching to second line ART and as a result reduce the overall cost of treatment and better patient outcomes.
Objectives of the study 1.4.1 Broad objective
To determine the factors associated with virologic failure amongst adults on antiretroviral therapy with suspected clinical and immunological treatment failure in Nyanza Region. 
Specific Objectives
Hypothesis
Virologic treatment failure is associated with age less than 40 years; male gender; baseline CD4 cell count below 100 and prolonged use of ART.
Literature review
Treatment failure is defined as clinical, immunological and virologic. The World Health Organization (WHO) defines clinical failure amongst adults and adolescents as new or recurrent clinical conditions indicating severe immunodeficiency (WHO clinical stage 4 conditions) after 6 months of effective treatment. Immunological failure as CD4 count falls to the baseline (or below); or persistent CD4 levels below 100 cells/mm 3 . Virologic failure as plasma viral load above 1000 copies/ml based on two consecutive viral load measurements after 3 months, with adherence support (WHO 2013).
The Kenya Ministry of Health in the guidelines for antiretroviral therapy in Kenya has additional criteria. Amongst adults, clinical failure amongst adults and adolescents as new onset of significant opportunistic infections (OIs) or malignancy, usually WHO stage 3 or 4 condition; recurrence of previously treated OI after at least 6 months of ARVs, downgrading of WHO classification in the course of follow up; unintentional weight loss in a patient who was doing well on ARVs without any overt signs and/or symptom. Immunological failure is defined as CD4 fall to or below pre-ART level or fall by 30% from on treatment peak value or CD4 levels persistently below 100 cells after treatment for at least 12 months of effective ART. Virologic failure is defined as viral load > 1000 copies/ml (Ministry of Medical Services 2011).
Treatment failure may occur due to various risk factors including previous treatment failure, drug resistance, poor adherence to treatment, poor absorption of ARVs, co-morbidities, poor health prior to initiation of ART, drug toxicity and drug interactions and substance abuse leading to poor adherence (US Department of Health and Human Services 2013). Non-adherence to ART is however noted as a key risk factor and a contributor to treatment failure (Ministry of Medical Services 2011). There are however other factors including age, gender, advanced HIV disease, low baseline CD4, ARV regimens and long periods on ART that are associated with treatment failure as indicated by several studies.
Age of the patient on treatment has been shown to affect virologic outcomes amongst patients initiated on ART by several studies though different age categories were considered. A study done in Thailand by Khienprasit and others showed that patients who were on ART and of age less than 40 years were more likely to have virologic failure (Khienprasit, Sirisanthana et al. 2011) . In a study comparing the median age between the control group with a median age of 42 years and patients with virologic failure and a median age of 38 years showed that the difference was statistically significant in favour of the 42 years age group (Parienti, Massari et al. 2004 ). Anude and others in a study in Nigeria using a viral load cut off of 400 copies/ml and that by Ramirez and others in a study in Mexico using a viral load cut off of 50 copies/ml showed that patients younger than 30 years of age were more likely to have virologic failure (Crabtree-Ramirez, Villasis-Keever et al. 2010, Anude, Eze et al. 2013 ). In a review of patients on ART enrolled for prevention of mother to child transmission (PMTCT) program and viral load requested to check for effectiveness of ARV regimens they were on and using a viral load cut off of 400 copies/ml, women who were 25 years of age or younger were more likely to have virologic failure (Ng'ang'a, Muttai et al. 2012 ). Other studies done in Peru and California in the United States of America (USA) also associated younger age with virologic failure (Chao, Tang et al. 2012 , Alave, Paz et al. 2013 ). The only study reviewed that showed no association between age and virologic failure was that done in Brazil (Tuboi, Harrison et al. 2005) .
Gender The level of CD4 cell count at baseline has been associated with treatment failure as shown by several authors. Different CD4 cell count cut offs were applied by different studies in determining virologic failure. In two studies done in Kenya and South Africa respectively using a cut off CD4 cell count of 50, it was found that patients with a CD4 cell count below 50 were more likely to have virologic failure ( In treatment of HIV, the use of triple ARVs is highly recommended to achieve the goal of treatment. Outcomes of treatment using different regimens may vary as indicated by Kwobah and others who registered no difference on treatment outcomes when comparing Stavudine to Zidovudine and Nevirapine to Efavirenz (Kwobah, Mwangi et al. 2012 ). Use of Nucleoside Reverse Transcriptase Inhibitors (NRTI) and NNRTI regimens were remotely associated with virologic failure in a Massachusetts study (Kwobah, Mwangi et al. 2012 ) though contrasting results by Robbins and others showed no significant difference to Ritonavir boosted regimens (Robbins, Daniels et al. 2007 ) and Crabtree and others who actually found use of NNRTI to be protective to virologic failure. In comparing Protease Inhibitors (PI) based regimen to NRTI only regimen, Chao and others recorded that use of NRTI only regimen were associated with virologic failure (Chao, Tang et al. 2012 ). In a Nigerian study, the outcomes of patients on Zidovudine (ZDV) based regimen were compared to those of Stavudine (D4T) 
Study area
The study area is Nyanza region formerly known as Nyanza Province and is located in southwest part of Kenya. It has a total population of 5.4 million people (KNBS 2010) distributed across six counties namely Kisumu, Kisii, Nyamira, Siaya, Homabay and Migori. Nyanza region has a size of 12,477.1 KM 2 and a population density of 440/Km 2 . The predominant tribe is Luo; others are Kuria, Kisii and Luhya. According to the Kenya AIDS Indicator Survey preliminary report of 2012, Nyanza has the highest HIV prevalence of 15.1 compared to the national which is estimated to be 5.6 (National AIDS and STI Control Program and Kenya Ministry of Health 2013) which translates to about 500,000 people living with HIV.
Study design
Cross sectional study based on a retrospective review of viral load test data in electronic database of patients with clinical and/or immunological failure with viral load test done from January to December 2012. The study design was selected based on its strengths that include ability to determine cause of the problem -which in this study is virologic failure amongst patients who have immunological and/or clinical failure; affordable; ability to estimate risk of an event which in this study is al failure and allows for accurate measurement of exposure variables.
Study population
In this study, data of adult patients on ART for ≥ 6 months with immunological and/or clinical treatment failure with viral load test done between January to December 2012 and data available in electronic database was reviewed to determine the factors associated with virologic failure was reviewed.
Sampling technique
Probability random sampling technique was used to select patients who were included in the sample. The records that were finally included in the analysis were selected randomly using a Microsoft Excel randomizer. The records which in Excel sheet were assigned serial numbers which guided selection of records once random numbers are generated. The selected records were assessed for completeness. If a record was incomplete and missing information cannot be corrected, it was replaced with the next randomly selected record until the desired sample size was achieved. Once the intended sample size was achieved, the records were put in a separate database for further cleaning and subsequent data analysis.
Sample size determination
Data used for this study was derived from electronic patient records from the viral load testing electronic database. A total of 1,919 patient records for viral load tests done in 2012 were reviewed. To determine the study population, patients with repeat viral load tests, patient from other provinces and paediatric data were first be excluded followed by any incomplete records that cannot be reconciled. A total of 9,284 records were finally included as indicated in figure 1 below: Because the estimated total population is less than 10,000 the following formula was applied to determine actual sample size required. nf = n 1+n N Where nf = is the desired sample size N= the estimated total population less than 10,000 n= estimated sample when the estimated total population (N) is greater than or equal to 10,000 nf = 384 = 320 1+384 1919 The final sample size that was included in the analysis was 320 records.
Data collection
Data for this study was collected as part of routine patient care and treatment by health care providers who as part of clinical care completed standardized viral load request forms designed using Teleform ® version 10.0 Software. The viral load request and result forms are used to collect relevant demographic, clinical and laboratory information. These forms once filled were then scanned into a password protected computer, verified, cleaned and finally stored into access based database. The data sheet shown in appendix I show the variables of interest abstracted from the electronic medical database to create dataset for analyses. This data will then be checked for any inconsistencies and the final variables picked for analysis.
Quality control
Inclusion and exclusion criteria Inclusion criteria: -To be included in this study, patients must have had a viral load test between 1 st January 2012 and 31 st December 2012; only first viral load test done in 2012 was considered; been older than 14 years of age at time of viral load test request and have complete records. Exclusion criteria: -Viral load test done as repeats (≤ 3 months from the initial); patient below 14 years and with incomplete results were excluded.
Validity and Reliability
Automation of data entry through scanning of forms eliminated the need for manual data entry and as a result minimizing errors. Information bias was minimized by using a designed standard data tool for data extraction to ensure that similar information was extracted from the database for all records included in the analysis. I additionally relied on accurate data in the electronic database. Integrity of data was ensured through data cleaning by checking for outliers and errors, eliminating duplicates and identifying and filling in missing data that were extracted using a data tool to ensure standardization of required information from each patient record.
Selection bias was minimized through random selection of records hence providing an equal opportunity to all patients whose records were in the electronic database. Lastly, confounding was minimized by ensuring that possible confounding factors such as age and sex are included in the multivariate analysis to deal with interaction of one variable on another that may otherwise result in a wrong conclusion on the effect of the variable on the outcome variable, virologic failure. Chances of inadvertent release of patient information were very remote because identifiers such as patient names were not included in the database used for analysis. Additionally, analysis database was stripped of patient personal identifiers.
Benefits:
No direct benefit was gained by the patients but the results will help improve care and treatment for future PLHIVs.
Informed Consent: Informed consent was not sought from the patients to review the data that had already been collected for the following reasons: Patients were not put at risk by this study because data had already been collected and entered into a database. The data analysis process required no contact with the patients and patients continued to receive care and treatment services in accordance with the standards of care in Kenya regardless of this study or its outcomes; rights of patients was not adversely affected; the information being analysed during this study had already been collected and seeking patient's informed consent before reviewing the data will not be done because some patients included in the database may have already defaulted and not be traceable.
Confidentiality:
Access to the database used in this study was limited to authorized persons; the database remained in a secured location and in a password protected computer and no individual patient(s) was identified when the results of this study are presented. All results were reported in an aggregate form.
Data processing and analysis
Data was reviewed for any inconsistencies, missing information and outliers which were then fixed. Data analysis was done using Statistical Package for Social Sciences (SPSS) version 12.0 for Windows (IBM, 2013). Additionally, Microsoft office Excel 2007 was used in creating graphs. A patient was considered to have virologic failure if the viral load is ≥1000copies/ml.
To describe the baseline demographic and clinical characteristics of patients, frequencies of patient characteristics such as age, gender, baseline, peak and current (at time of viral load test request) CD4 cell count by categories and type of regimen (1 st or 2 nd line ART) was done. Median was also computed for continuous variables like age, CD4 and period on ART because median is not much affected when variables are not normally distributed.
Univariate analysis was done to determine the rates of virologic failure. To determine factors associated with virologic failure, odds ratio (OR) was calculated in bivariate analysis. Factors presumed to be associated with failure and with p values of <0.25 from the bivariate analysis were then be included in the multivariate analysis (adjusting for age and gender). The cut off p value of <0.25 was chosen based on the works of Bendel and Afifi(Bendel and Afifi 1977) and Mickey and Greenland (Mickey and Greenland 1989) which showed that this cut off point allows for the inclusion of all important variables even though it also has the disadvantage of including variables with questionable importance (Hosmer and Lemeshow 2000) .
Risk factors analyzed included age, gender, baseline CD4 cell counts dichotomized into two groups (less than or equals 200 mm 3 
Study constraints and limitations of the study
This study had several limitations. First, some patient demographic and clinical information such as marital status, occupation, disclosure of HIV status, employment status, economic status, clinical status (WHO stage) and distance of residence from the health facility were not included because they were not readily accessible; Secondly, baseline viral load test was not routinely done due to resource limitation and only recommended in patients suspected to have failed treatment hence was not included in the analysis. Thirdly, incomplete data may also be a limitation. 
Demographic and clinical characteristics of patients
Amongst the patients with suspected ART treatment failure and viral load test requested to confirm failure, the median age was 39 years; 186 (58.1%) were female; 173 (54.1%) and 147 (45.9%) were aged ≤ 40 and > 40 years respectively; only 6 (1.9%) had missed ARVs for a period of more than 2 weeks; 31 (9.7%) had missed ARVs due to missing clinic visits; majority (30.6%) of the patients had been on ARVs for more than 4 years at the time of viral load request; 206 (64.4%) of patients had immunological failure as a reason for requesting for viral load test; majority (96.9%) of the patients were on first line ART regimen; 208 (65.2%) had baseline CD4 less than 100 cells/mm 3 ;baseline median CD4 at start of ART was 152 cells/mm 3 , peak median was 336 cells/mm 3 and median CD4 at the time of viral load request was 170 cells/mm 3 as detailed in table 1 and figures 2-7 below. Table 2 below shows the risk of virologic failure per category of patients. In gender, risk of failure amongst males and females was 43.3% and 37.6% respectively. The difference in risk of failure was however no statistically significant. Looking at the different age groups, risk of failure was 48% and 30.6% amongst patients in the ≤ 40 and >40 years age groups; the difference in risk of failure in the different age groups was significant with a p value of 0.0001.
Amongst patients who had missed ARVs in the last two weeks prior to viral load request, 50% had virologic failure compared to 39.8% amongst those who had not missed ARVs and the difference was not of statistical significance. In comparing the risk of virologic failure amongst patients who had missed ARVs due to missed clinic visit (32.3%) to those who had not missed (41%), the difference was not of statistical significance. Looking at the risk of virologic failure by length of time that patients have been on ART, risk of failure was as follows, 47.8% in ≤ 1 year group, 39% in > 1 year to 2 years, 41.7% in > 2 years to 3 years, 38% in > 3 years to The risk of failing based on the regimen the patient was taking, 39.4% of those on first line ART had virologic failure compared to a higher risk of 60% amongst patients on second line. The difference in risk was however not of statistical significances. The difference between patients with CD4 ≤ 100 cells/mm 3 (47.7%) and those with CD4 > 100 100 cells/mm 3 (36.1%) was statistically significance with a p value of 0.0001. 
Factors associated with virologic failure Bivariate analysis -unadjusted odds ratio
In bivariate analysis, the only patient characteristic that had statistical difference was age. The chances of patients in the ≤ 40 years age group failing treatment in comparison to the >40 years one was 2.10 times higher and was of statistical significance (p-value 0.0017).
The differences in other patient characteristics including gender, missing ARVs for two weeks prior to viral load test request, missing ARVs due to missing clinic visit, period of time on ART, indications or reasons for viral load request, ARV regimen and CD4 cell count were not of statistical significance as shown in details in table.3 below.
Multivariate analysis -adjusted odds ratio
In multivariate analysis and adjusting for possible confounders, age was the only patient characteristic that had statistically significant difference upon comparison. Patients who were younger than 40 years had 2.33 (p value 0.0011) chance of failing treatment.
The differences in other patient characteristics including missing ARVs for two weeks prior to viral load test request, missing ARVs due to missing clinic visit, period of time on ART, ARV regimen, CD4 and indication for viral load testing were not of statistical significance as shown in details in In this study, amongst the patients with suspected ART treatment failure and viral load test requested to confirm failure, the median age was found to be 39 years; 186 (58.1%) were female; 173 (54.1%) aged 40 years or younger; only 6 (1.9%) had missed ARVs for a period of more than 2 weeks; 31 (9.7%) had missed ARVs due to missing clinic visits; majority (30.6%) of the patients had been on ARVs for more than 4 years at the time of viral load request; 206 (64.4%) of patients had immunological failure as a reason for requesting for viral load test; majority (96.9%) of the patients were on first line ART regimen; 208 (65.2%) had CD4 cell count more than 100; baseline median CD4 at start of ART was 152 cells/mm 3 , peak median was 336 cells/mm 3 and median CD4 at the time of viral load request was 170 cells/mm 3 . There was no study reviewed that had detailed out demographic and clinical characteristics in a similar pattern for comparison.
Factors associated with virologic failure
In this study, gender was found not to be associated (AOR 1.51, p value 0.1069) with virologic failure. This is supported by studies that showed no association of male gender to virologic failure. Studies by Khienprasitet. al. In determining whether the regimen that the patient was given at initiation has any association with treatment failure, there was no association (AOR 0.51, p value 0.3482) recorded. This is supported by results recorded by Robbins and others (Robbins, Daniels et al. 2007 ) and Crabtree and others (Crabtree-Ramirez, Villasis-Keever et al. 2010). Results in this study were however in contradiction to those recorded by Kwobah and others (Kwobah, Mwangi et al. 2012 ) who showed that NRTI and NNRTI based are remotely associated with treatment failure and Chao and others (Chao, Tang et al. 2012 ) who registered results showing that patients on NRTI only based regimen are associated with treatment failure. However, the study did not measure association between NRTI only based regimen and treatment failure.
The study was however unable to evaluate other factors including WHO clinical staging, hazardous alcohol intake, previous exposure to ARVS through e.g. Prevention of Mother to Child Transmission (PMTCT), co-morbidities during ART intake, baseline haemoglobin, marital status, Employment status, sexual orientation, patient residence (urban or rural) and disclosure which have been documented as factors associated with treatment failure.
Conclusion
Based on the results of this study, the key factor associated with virologic failure amongst patients with suspected treatment failure is age lower than 40 years hence present a problem that need to be addressed.
Recommendations
Based on the findings of this study, recommendations include: 1. Focus on patients younger than 40 years should be prioritized to ensure better treatment outcomes and avoidance of treatment failure. This is to facilitate identification of possible barriers to treatment and developing possible solutions.
2.
Comprehensive and focused services that is friendly to the young need to be strengthened at the health facility level. This is to ensure that services that are responsive to the need of the young patients on treatment are implemented.
